Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk
Diabetes · 2025
DOI: 10.2337/db24-0958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Kehan Bao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, NY. Hauptthemen laut MEDLINE: Glucagon-Secreting Cells, Cyclic AMP-Dependent Protein Kinases, Liver, Receptors, Glucagon. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Glucagon stimulates hepatic glucose production, in part by promoting the uptake and catabolism of amino acids. Inhibition of the liver glucagon receptor (GCGR) results in elevated plasma amino acids, which triggers the proliferation of pancreatic α-cells, forming a liver–α-cell loop. This study aims to delineate hepatic signaling molecules downstream of GCGR that mediate the liver–α-cell loop. We knocked down liver GCGR, its G-coupled protein GNAS, and two GNAS downstream effectors, PKA and EPAC2 (RAPGEF4). Mice with GCGR, GNAS, and PKA knockdown had similar suppression of hepatic amino acid catabolism genes, hyperaminoacidemia, and α-cell hyperplasia, but those with EPAC2 knockdown did not. We then demonstrated that activating liver PKA was sufficient to reverse hyperaminoacidemia and α-cell hyperplasia caused by GCGR blockade. These results suggest that liver GCGR signals through PKA to control amino acid metabolism and that hepatic PKA plays a critical role in the liver–α-cell loop. Article Highlights A liver–α-cell loop exists, where inhibition of the liver glucagon receptor (GCGR) causes hyperaminoacidemia and pancreatic α-cell hyperplasia, but the GCGR downstream factors responsible for these effects are not clear. We silenced GCGR, its G-coupled protein GNAS, and two GNAS downstream effectors, PKA and EPAC2, to assess their effects on the liver–α-cell loop. Inhibition of the GCGR-GNAS-PKA pathway suppresses amino acid catabolism and causes α-cell hyperplasia, whereas PKA activation promotes amino acid catabolism and reduces alpha cell mass even when GCGR is blocked. Our study establishes hepatic PKA as the critical regulator of the liver–α-cell loop.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Tarrytown, NY.
ORCID-Profile: Haruka Okamoto
Förderung
- Regeneron Pharmaceuticals
Zitieren
APA
Bao, K., Berger, J., Na, E., Su, Q., Halasz, G., Sleeman, M., & Okamoto, H. (2025). Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk. Diabetes. https://doi.org/10.2337/db24-0958
Vancouver
Bao K, Berger J, Na E, Su Q, Halasz G, Sleeman M, et al. Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk. Diabetes. 2025. doi:10.2337/db24-0958
BibTeX
@article{Bao2025,
author = {Bao, Kehan and Berger, Jason and Na, Erqian and Su, Qi and Halasz, Gabor and Sleeman, Mark and Okamoto, Haruka},
title = {Hepatic PKA Mediates Liver and Pancreatic α-Cell Cross Talk},
journal = {Diabetes},
year = {2025},
doi = {10.2337/db24-0958}
}
EUVIMED